Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma

Launched by DI DENG · May 5, 2015

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a special type of low-dose radiation therapy called low-dose involved-field radiation therapy (LD-IFRT) for patients with recurrent advanced follicular lymphoma. The goal is to see if this treatment can help patients under 65 years old who have had their lymphoma come back after previous treatments. Many studies have suggested that this low-dose radiation can lead to good responses in patients, but previous trials didn't show long-lasting results compared to other treatments.

To be eligible for this trial, patients need to be between 18 and 65 years old, have confirmed follicular lymphoma (a type of cancer), and have experienced a recurrence of the disease after initial management. They should also be in generally good health and not pregnant. Participants will receive the low-dose radiation therapy and will be monitored for how well it works and any side effects. Importantly, patients can choose to leave the trial at any time if they wish. This trial aims to provide valuable information that could improve treatment options for younger patients with this form of lymphoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Both male and female aged range from 18 years to 65 years.
• • Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1.
• • All patients had histological confirmed follicular lymphoma Grade 1 or 2.
• • Recurrent patient with stage III and IV after initial management.
• • Had the indications for treatment provided by GELA.
• • Rituximab is too expensive to be managed for the patient.
• • Adequate organ function.
• • Negative pregnancy test.
• • Signed informed consent document on file.
• Exclusion Criteria:
• • Woman who were pregnant or lactating.
• • Had uncontrolled metastases in central nervous system.
• • With severe local infection or general infective disease.
• • Immunotherapy for the treatment of follicular lymphoma within 1 month prior to the start of this trial.
• • With other second primary malignancy except cutaneum carcinoma.
• • Being or planing to participate in other study.
• • Any patient who in the opinion of the investigator should not participate in the study.
• Withdrawal Criteria:
• • Patient are free to withdrawal completely from the study at any time upon request.
• • Patient in the study may be stopped with the patient agreement at any time at the discretion of investigator.
• • Continual consolidation chemotherapy after irradiation within the follow-up period.
• • In-field progression on irradiation ongoing.
• • Poor tolerability adverse events in the period of chemotherapy or irradiation after enrolled in the study.